



Berkshire West Area Prescribing Committee

Drug Name	Lycopene (Ateronon®)		
Indication under review	Lipid modification		
Policy No:	APC 051		
Date of Issue/ Date of reissue:	January 2014/ March 2017		
Review Date:	March 2020		
Policy Statement:	Lycopene (Ateronon®) is not recommended as an option for lipid modification within Berkshire West.		
Traffic Light Status	Brown		
Key Points considered:	<ul style="list-style-type: none"> - As this is a food supplement it is difficult to get information other than from websites selling the product. - Does not have product license as is a food supplement. - Evidence for safety and efficacy of lycopene is very limited with only trial of short duration without patient-orientated outcomes. - Does not affect lipid levels. - This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget 		
References:	<ol style="list-style-type: none"> 1. Ahuja KD et al. Effects of olive oil and tomato lycopene combination on serum lycopene, lipid profile, and lipid oxidation. Nutrition. 2006 Mar;22(3):259-65. Epub 2006 Jan 18. 		
Date taken to APC:	1 st March 2017		
Date Ratified by GP MOC on Behalf of Board:	15 th March 2017		

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only